Over the last several months, NCL’s GLP-1 advocacy has had a real impact. Our national survey of 1,500 women exposed widespread confusion and misinformation about compounded GLP-1 weight loss drugs—evidence that helped elevate public awareness of the risks posed by unregulated products. NCL spearheaded an effort joined by 12 public health organizations to petition the FTC to investigate telehealth platforms that use deceptive marketing to promote compounded GLP-1s. This effort has strengthened pressure on regulators to crack down on misleading claims and promote consumer protections.

NCL amplified growing safety concerns by praising the FDA’s updated warnings and highlighting more than 1,150 reported adverse events tied to compounded GLP-1s. The Weight Truth Campaign is educating consumers about how to verify FDA approval status, consult trusted healthcare providers, avoid unsafe telehealth prescribing practices, and use only licensed pharmacies.

Finally, NCL sounded the alarm on emerging insurance coverage rollbacks that threaten access to FDA-approved GLP-1 treatments. We were pleased with the Trump Administration for negotiating lower prices for the popular brands.  Through our report Reversing Progress on Obesity Care,  we urged policymakers to provide coverage given the significant health and economic benefits these medications provide. Our efforts are paying off: regulators are expanding coverage, the public is better informed, and momentum is growing for stronger protections in the rapidly evolving GLP-1 marketplace.